Docetaxel nanoparticle - Cristal Therapeutics

Drug Profile

Docetaxel nanoparticle - Cristal Therapeutics

Alternative Names: CriPec® docetaxel

Latest Information Update: 25 Jan 2017

Price : $50

At a glance

  • Originator Cristal Therapeutics
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 19 Jan 2017 Cristal Therapeutics plans a phase Ib trial in Solid tumours
  • 13 Jan 2017 Cristal Therapeutics plans a phase IIa trial for Solid tumours (Cristal Therapeutics pipeline, January 2017)
  • 29 Sep 2015 Phase-I clinical trials in Solid tumours in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top